Literature DB >> 9756770

Mechanism of fluconazole resistance in Candida krusei.

A S Orozco1, L M Higginbotham, C A Hitchcock, T Parkinson, D Falconer, A S Ibrahim, M A Ghannoum, S G Filler.   

Abstract

The mechanisms of fluconazole resistance in three clinical isolates of Candida krusei were investigated. Analysis of sterols of organisms grown in the absence and presence of fluconazole demonstrated that the predominant sterol of C. krusei is ergosterol and that fluconazole inhibits 14alpha-demethylase in this organism. The 14alpha-demethylase activity in cell extracts of C. krusei was 16- to 46-fold more resistant to inhibition by fluconazole than was 14alpha-demethylase activity in cell extracts of two fluconazole-susceptible strains of Candida albicans. Comparing the carbon monoxide difference spectra of microsomes from C. krusei with those of microsomes from C. albicans indicated that the total cytochrome P-450 content of C. krusei is similar to that of C. albicans. The Soret absorption maximum in these spectra was located at 448 nm for C. krusei and at 450 nm for C. albicans. Finally, the fluconazole accumulation of two of the C. krusei isolates was similar to if not greater than that of C. albicans. Thus, there are significant qualitative differences between the 14alpha-demethylase of C. albicans and C. krusei. In addition, fluconazole resistance in these strains of C. krusei appears to be mediated predominantly by a reduced susceptibility of 14alpha-demethylase to inhibition by this drug.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756770      PMCID: PMC105912     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity.

Authors:  D C Lamb; D E Kelly; W H Schunck; A Z Shyadehi; M Akhtar; D J Lowe; B C Baldwin; S L Kelly
Journal:  J Biol Chem       Date:  1997-02-28       Impact factor: 5.157

3.  Purification and properties of cytochrome P-450-dependent 14 alpha-sterol demethylase from Candida albicans.

Authors:  C A Hitchcock; K Dickinson; S B Brown; E G Evans; D J Adams
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

4.  The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs.

Authors:  K Venkateswarlu; D W Denning; S L Kelly
Journal:  J Med Vet Mycol       Date:  1997 Jan-Feb

6.  Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation.

Authors:  S L Kelly; D C Lamb; D E Kelly; N J Manning; J Loeffler; H Hebart; U Schumacher; H Einsele
Journal:  FEBS Lett       Date:  1997-01-02       Impact factor: 4.124

7.  Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance.

Authors:  K Venkateswarlu; D W Denning; N J Manning; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.

Authors:  D Sanglard; F Ischer; L Koymans; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

9.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility.

Authors:  A Geber; C A Hitchcock; J E Swartz; F S Pullen; K E Marsden; K J Kwon-Chung; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more
  49 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Secreted aspartate proteinases, a virulence factor of Candida spp.: occurrence among clinical isolates.

Authors:  P Hamal; J Dostál; V Raclavský; M Krylová; I Pichová; O Hrusková-Heidlngsfeldová
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

Review 4.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

5.  Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species.

Authors:  Chien-Ching Hung; Yun-Liang Yang; Tsai-Ling Lauderdale; L Clifford McDonald; Chin-Fu Hsiao; Hsiao-Hsu Cheng; Yong An Ho; Hsiu-Jung Lo
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

6.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

7.  In vitro antifungal activity and cytotoxicity of a novel membrane-active peptide.

Authors:  S Y Hong; J E Oh; K H Lee
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

9.  Candida albicans and Candida tropicalis in oral candidosis: quantitative analysis, exoenzyme activity, and antifungal drug sensitivity.

Authors:  Karen Regina Carim da Costa; Joseane Cristina Ferreira; Marilena Chinali Komesu; Regina Celia Candido
Journal:  Mycopathologia       Date:  2008-09-12       Impact factor: 2.574

10.  Blood stream infections by Candida glabrata and Candida krusei: a single-center experience.

Authors:  Hee Kyoung Choi; Su Jin Jeong; Han Sung Lee; Bum Sik Chin; Suk Hoon Choi; Sang Hoon Han; Myung Soo Kim; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.